

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1719380> since 2022-10-12T09:33:57Z

Published version:

DOI:10.1530/EJE-18-0923

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

1 **Title page**

2 Title: Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at
3 high risk of recurrence: the experience of the San Luigi Gonzaga Hospital.

4

5 Authors: A. Calabrese¹ MD, V. Basile¹ MD, S. Puglisi¹ MD, P. Perotti¹ BD, A. Pia¹ MD, L.
6 Saba¹ BD, P. Berchiolla² PhD, F. Porpiglia³ MD, A. Veltri⁴ MD, M. Volante⁵ MD, G.
7 Reimondo¹ MD, A. Berruti⁶ MD, M. Terzolo¹ MD.

8 Institutions:

9 ¹Internal Medicine, Dept. of Clinical and Biological Sciences, S. Luigi Gonzaga Hospital,
10 Orbassano, University of Turin, Italy

11 ²Statistical Unit, Dept. of Clinical and Biological Sciences, Orbassano, University of Turin,
12 Italy

13 ³Urology, Dept. of Oncology, S. Luigi Gonzaga Hospital, Orbassano, University of Turin, Italy

14 ⁴Radiology, Dept. of Oncology, S. Luigi Gonzaga Hospital, Orbassano, University of Turin,
15 Italy

16 ⁵Pathology, Dept. of Oncology, S. Luigi Gonzaga Hospital, Orbassano, University of Turin,
17 Italy

18 ⁶Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public
19 Health Medical, ASST-Spedali Civili, University of Brescia, Brescia, Italy

20

21 Corresponding author: Dr. Soraya Puglisi, MD

22 Internal Medicine, Dept. of Clinical and Biological Sciences, University of Turin

23 S. Luigi Gonzaga Hospital: Regione Gonzole 10, Orbassano (TO) 10043, Italy

24 (+39) 320 8527961, sorayapuglisi@yahoo.it

25

26 Brief title: Mitotane in high risk adrenal cancer.

27

28 Key words: Adrenocortical carcinoma, Adjuvant therapy, Mitotane, Recurrence, Survival.

29

30 Word count: 3290

31 **Abstract**

32 Objective. Many patients with adrenocortical carcinoma (ACC) suffer from tumor recurrence
33 despite radical surgery. Evidence on the post-operative use of mitotane is controversial and no
34 predictors of response are available. We aimed to assess whether adjuvant mitotane treatment
35 may prolong survival in patients with non-metastatic ACC following complete resection and
36 whether ACC patients at high risk of recurrence may benefit from treatment.

37 Design and Methods. We retrospectively reviewed data from 152 non-metastatic ACC patients
38 followed at the San Luigi Gonzaga Hospital: 100 patients were treated with adjuvant mitotane
39 and 52 patients were left untreated following surgery. We assessed a number of potential
40 predictive factors of recurrence and death. Mitotane effect was explored stratifying patients by
41 hormone secretion (yes vs no), staging (stage I-II vs stage III) and Ki67 index.

42 Results. The control group had a higher risk of recurrence (HR 2.79, 95%CI 1.58-4.91;
43 $p<0.001$) than mitotane group, while overall survival was not significantly different between
44 groups. Hormone secretion, elevated Weiss score and elevated Ki67 index confer a higher risk
45 of both recurrence and death, and stage III ACC of death. Adjuvant mitotane treatment reduced
46 significantly the risk of death in patients with elevated Ki67 index ($p=0.005$), and in patients
47 with stage III ACC ($p=0.02$).

48 Conclusions. Adjuvant mitotane may prolong recurrence-free survival in radically resected
49 ACC patients with acceptable toxicity and may also prolong overall survival in a subgroup of
50 ACC patients at high risk of recurrence.

51 **Introduction**

52 Adrenocortical carcinoma (ACC) is a rare endocrine neoplasia, with a reported incidence of
53 about two cases per million population per year, which affects more frequently the female sex
54 and has a peak incidence in the middle age (1). ACC is characterized by an overall dismal
55 prognosis and its clinical manifestations are either the consequence of steroid excess or mass
56 effect; however, ACC is increasingly found as an adrenal incidentaloma (2). Surgery is the
57 cornerstone of ACC management and the most effective treatment, while survival is poor when
58 surgical removal of ACC is unfeasible (3). Although radical surgery can be potentially curative,
59 many ACC patients will suffer tumour recurrence following apparently curative resection.
60 Prevention of tumour recurrence is of the utmost importance because recurrence impairs
61 significantly life expectancy and quality of life of affected patients (1),(4). Therefore, adjuvant
62 concepts look sound and the post-operative use of mitotane as an adjuvant therapy following
63 ACC removal has been the most followed approach (5).

64 Reported outcomes of adjuvant mitotane therapy have been conflicting between studies and,
65 lacking data from randomized controlled trials, evidence is based only on retrospective studies
66 (6),(7) which were often underpowered and did not always include a concomitant control group
67 of untreated patients (5). Previous research from our group showed that adjuvant mitotane was
68 associated with longer recurrence-free survival (RFS) in treated patients with radically resected
69 ACC compared to untreated patients. In that study, confounding by indication was reduced
70 comparing two management strategies applied in different settings and treatment was given
71 according to the centre attitude toward adjuvant mitotane (i.e. all patients of a given centre were
72 treated or not treated) (8). In 2017, we updated the results of our earlier study after nine
73 additional years of follow-up and confirmed that adjuvant mitotane was associated with
74 prolonged RFS (9). Controversy on adjuvant mitotane still lives, however, as demonstrated by
75 a study published in 2016 showing that adjuvant mitotane therapy was associated with

76 decreased RFS (10). Moreover, the available literature provides scant information on how
77 treatment was delivered (dosing regimen, duration of treatment, circulating levels, etc.) and
78 none of the studies could identify whether outcome of patients at high risk of recurrence is
79 improved with adjuvant mitotane treatment. This information is key considering that adjuvant
80 mitotane is currently recommended in high-risk patients (7).

81 To contribute to the debate on post-operative adjuvant mitotane therapy, we reviewed
82 retrospectively our experience at the San Luigi Gonzaga Hospital, a tertiary centre for the care
83 of ACC patients in Italy. The main aims of the study were to assess whether adjuvant mitotane
84 treatment may prolong survival in patients with non-metastatic ACC following complete
85 resection and whether ACC patients at high risk of recurrence may benefit from treatment.

86 **Materials and methods**

87 At the San Luigi Gonzaga Hospital, we established in 2001 the Adrenocortical Carcinoma
88 Database with the development of a structured data form to collect comprehensive information
89 of ACC patients managed at our centre. Data were obtained from patient interviews and
90 available medical documentation and were processed by skilled and experienced personnel. In
91 case of missing information, further data were actively requested to medical institutions where
92 patients have been previously managed. For the purpose of this study, we retrieved data of
93 patients who underwent radical surgery from July 2001 to July 2015. Due to the referral pattern
94 of our centre, most patients have been operated on at other institutions (7% of patients had
95 surgery in our centre) and were referred to us after a histologic diagnosis of ACC was secured
96 for considering adjuvant medical therapy. Follow up for this study was closed in May 2017.
97 The institutional ethics committee of our hospital approved the study and all patients provided
98 written informed consent.

99 Inclusion criteria of the study were: age ≥ 16 years; pathologically confirmed diagnosis of ACC
100 according to Weiss score (11) (81% of pathological diagnoses were reviewed at our centre);
101 ENSAT stage I-III at diagnosis; complete macroscopic resection, defined as R0, R1 or RX
102 resection on the basis of surgical and pathologic reports; availability of pre-operative and post-
103 operative computed tomography (CT) or magnetic resonance imaging (MRI) scans; complete
104 follow-up information. Exclusion criteria were: incomplete tumour staging, ENSAT stage IV,
105 history of other previous or concomitant malignancies, R2 resection; recurrence or death before
106 the landmark point of three months; incomplete follow-up information, concomitant adjuvant
107 chemotherapy and radiotherapy or both, and patient inclusion in previous studies.

108 Patients charts were reviewed and the following information was retrieved for the study:
109 patient's age and sex, date of diagnosis, imaging data, ACC stage, clinical presentation
110 including assessment of hormone secretion, type of surgery, pathology report, adjuvant

111 treatment, date and type of recurrence, treatment of recurrence, last follow up, or death. Date
112 of diagnosis was defined as the date of surgery and conversion to open adrenalectomy was
113 considered as open surgery. Completeness of surgery was established by R status: R0, free
114 resected margins; R1, microscopic involvement of resected margins; RX, not determined, and
115 R2, macroscopic invasion of resected margins. Tumour stage was established according to the
116 ENSAT classification (I-II, confined tumour; III, positive lymph nodes or infiltrating
117 neighbouring organs/veins without distant metastases; IV, distant metastases (12). Biochemical
118 confirmation of hormone excess was requested to categorize an ACC as hormone secreting.
119 Patients were stratified for Ki67 index ($Ki67 \leq 10\%$ and $Ki67 > 10\%$). Date of recurrence was
120 defined as the date of radiological evidence of a new lesion. Recurrence was described as 'local'
121 (involving the adrenal region), 'single distant' (one affected organ), or 'multiple distant' (more
122 than one affected organ). If adjuvant mitotane therapy was instituted, we analysed mitotane
123 levels on treatment, duration of treatment, reasons of treatment discontinuation, and severe
124 toxicity. Mitotane levels were attained by the Lysosafe® service since July 2005 while in the
125 preceding years we got data from in-house measurements, as previously described (13).
126 Duration of treatment was calculated from the date of initiation of therapy until ACC
127 recurrence, or discontinuation of treatment, or end of follow up, whatever occurring first.
128 From a total of 217 ACC patients on database, 152 patients fulfilled inclusion/exclusion criteria
129 and were retrospectively included in the study (Figure 1). Of these, 100 patients underwent
130 adjuvant mitotane therapy after initial surgery (mitotane group) and 52 patients were not treated
131 with any adjuvant treatment following surgery (control group). Patient management included
132 follow-up visits, imaging, hormone assessment, routine laboratory tests and measurement of
133 mitotane level for treated patients, every 3-4 months. Mitotane was given according to a low-
134 dose monitored regimen, as previously detailed (14). Briefly, treatment is started at 1 g daily
135 with further dose increase every 4-7 days up to 8-12 g daily, or the maximum tolerated dose.

136 Mitotane dose is adjusted to patient tolerability and drug levels that are regularly monitored
137 aiming at plasma concentration of 14-20 mg/L. Severe mitotane related effects leading to
138 hospitalization or treatment discontinuation, either more than three months or permanent, were
139 analysed for the study.

140 **Outcomes**

141 The main aims of our study were to compare recurrence free survival (RFS) and overall survival
142 (OS) in patients who received adjuvant mitotane therapy after complete macroscopic resection
143 with that of patients who did not receive adjuvant therapy and to identify whether outcome of
144 high-risk patients is improved with treatment. RFS was calculated from the time of initial
145 surgery to the first radiological evidence of recurrence. OS was calculated from the date of
146 initial surgery to the date of death. The following potential predictive factors for either RFS or
147 OS were investigated: patient sex and age, tumour stage, hormone secretion, cortisol excess,
148 type of surgery, R status, Weiss score, Ki67 index, adjuvant mitotane, and plasma mitotane
149 levels. Mitotane effect was explored stratifying patients by staging (stage I-II vs stage III),
150 hormone secretion (yes vs no), and Ki67 index.

151 **Statistical analysis**

152 Categorical data are presented as counts and percentages. Continuous data are presented as
153 medians and ranges. Differences in categorical variables were analysed by means of the Chi-
154 Square Test while differences in continuous variables by the two-tailed Mann-Whitney U test.
155 The survival distribution was assessed by the Kaplan-Meier product-limit methods and survival
156 curves were compared by the log-rank test. Patients who did not experience the event
157 (recurrence or death) were censored at the date of the last follow-up visit for the specific
158 survival analysis. Cox proportional hazards regression models were fitted to determine
159 predictive factors on RFS and OS. Proportional hazard assumption was verified by

160 Schoenfeld's residuals and by the log minus log method. To reduce the inherent bias of patients
161 with early progression or death, all survival analyses were performed with the landmark
162 method. Patients who experienced the event (recurrence or death) before the landmark point at
163 three months were excluded from the analyses. Complete case analysis was used. All reported
164 P values are two-sided. P-values of less than 0.05 were considered as statistically significant.
165 Statistical analyses were done with R Version 3.4.3.

166 **Results**

167 **Patients**

168 Baseline characteristics of patients are reported in Table 1. Female sex was mostly affected
169 (61.8%) and median age at diagnosis was 46 years [range, 16-77]. ACC was stage I-II in 75.7%
170 and hormone secreting in 47.4% of cases; cortisol was the most frequently secreted hormone,
171 alone or in combination with other steroid hormones. Secreting ACCs were mostly found in
172 women and in younger patients and had higher Ki67 index (Table 2). Surgery was done as an
173 open approach in 71.6% of cases; 63.5% in stage I-II and 94.6% in stage III ACC. R0 resection
174 was attained in 74.2% of open surgery vs 76.9% of laparoscopy. Median Weiss score was of 6
175 [3-9] with a median Ki67 of 20% [1%-70%]; 67.2% of ACC had Ki67 >10%. The median
176 follow-up was 51 months, 57 in the mitotane group vs 45 months in the control group. The
177 mitotane and control group were evenly distributed according to patient sex, ACC stage,
178 hormone secretion, type of surgery, and R status. The patients of the mitotane group were
179 younger and showed higher Weiss score and Ki67 index than the control group (Table 3).

180 Among mitotane treated patients, 47% of them began adjuvant treatment within one month after
181 surgery, 44% within three months, and the remaining 9% between 4-10 months. In 62.8% of
182 patients the therapeutic range of mitotane concentrations (14-20 mg/L) was maintained in at
183 least 50% of measurements. The patients who maintained the therapeutic range did not show a
184 significant reduction in the risk of recurrence (HR 0.79, [0.41-1.50], p=0.47). Median duration
185 of treatment was 21 months (14 months in patients who developed recurrence vs 45 months in
186 patients without recurrence). Causes of treatment discontinuation were toxicity (n=11), poor
187 compliance (n=7) or concomitant diseases (n=4). Unwanted effects of mitotane therapy mainly
188 affected the gastrointestinal system, and are reported in Table 4.

189 **Outcomes**

190 Recurrence occurred in 62.5% of cases: 56.5% of stage I-II and 81.1% of stage III ACC. The
191 median RFS of the overall cohort was 25 months [4-199]. Recurrence was mostly observed
192 within five years after surgery (93.5%), as showed in Figure 2. Only six patients recurred after
193 five years; they had stage II ACC with a Ki67 \leq 10% in three cases and no secretion in four of
194 them. Recurrence occurred in 55 patients of the mitotane group (55%) and in 40 of the control
195 group (76.9%). The median RFS was 36.5 months [4-199] in the mitotane group and 21 months
196 [4-180] in the control group. RFS of the two groups were significantly different when compared
197 with Kaplan Meier survival analysis ($p < 0.001$) (Figure 3). Univariate analysis showed that
198 stage, hormone secretion, Weiss score, Ki67 index, and adjuvant mitotane treatment were
199 independent predictors of recurrence (Table 5). Multivariate analysis confirmed hormone
200 secretion, Weiss score, and Ki67 index as predictive factors of recurrence (Table 6). After
201 adjusting for prognostic factors, the control group had a higher risk of recurrence (HR 2.79,
202 95% CI 1.58-4.91; $p < 0.001$) than the mitotane group (Figure 4).

203 Local recurrence occurred in 20% of cases, single distant recurrence in 42.2%, and multiple
204 distant recurrences in 37.8%. Loco-regional treatments, including surgery or radiofrequency
205 ablation, were used in 57.6% of ACC recurrence, while 31.5% underwent systemic therapy,
206 such as mitotane alone (17.2%) or in combination with chemotherapy (82.8%). Two patients
207 did not receive any treatment, six patients received multiple treatments, and two additional
208 patients received other types of treatment.

209 Death occurred in 42.1% of cases; 33% of stage I-II and 70.3% of stage III ACC. The median
210 OS of the overall cohort was 57 months [4-231]. Death occurred in 40% patients of the mitotane
211 group and in 46.2% of the control group. The median OS was 57.5 months [8-199] in the
212 mitotane group and 50.5 months [4-231] in the control group. Kaplan Meier analysis did not
213 find a significant difference between groups ($p = 0.85$) (Figure 5). Univariate analysis showed

214 that stage, Weiss score, and Ki67 index were independent predictors of OS (Table 5).
215 Multivariate analysis confirmed stage, hormone secretion, Weiss score, and Ki67 index as
216 predictive factors of OS (Table 6). After adjusting for prognostic factors, OS was not different
217 between the control group and the mitotane group (HR 1.22, 95% CI 0.61-2.42; p=0.57) (Figure
218 6).
219 Mitotane treatment reduced significantly the risk of both recurrence and death in patients with
220 elevated Ki67 index and the risk of death in patients with stage III ACC. Mitotane treatment
221 was not associated with any difference in survival between patients with secreting or non-
222 secreting ACC (Table 7).

223 **Discussion**

224 The rarity of ACC has hampered the implementation of large studies, so that only two
225 randomized controlled trials on treatment of advanced ACC are available up to now (15),(16)
226 and no randomized study has been conducted in the adjuvant setting. Therefore, evidence on
227 the efficacy of adjuvant mitotane treatment relies on six retrospective studies that included a
228 concomitant control group of untreated patients to allow a comparative assessment of treatment
229 efficacy (9),(10),(17),(18),(19),(20). The multicentre nature of some studies (9),(10),(20)
230 carries the disadvantage of an inherent heterogeneity in the management of ACC patients and
231 in the modalities of delivering mitotane therapy (i.e. dosing, duration of treatment). Most
232 importantly, no information on the key issue of what characteristics are associated with benefit
233 from adjuvant mitotane treatment can be retrieved from these studies.

234 In the present study, we report on our experience with adjuvant mitotane treatment at the San
235 Luigi Gonzaga Hospital, a tertiary centre for ACC patients in Italy. None of the patients has
236 been included in previous studies. The major findings of the present study are the observation
237 that adjuvant mitotane may prolong RFS and the identification of subgroups of patients that
238 may particularly benefit from treatment. Moreover, we defined predictive factors for recurrence
239 and death.

240 As expected, patients treated with adjuvant mitotane had worse prognostic factors (higher
241 Weiss score and Ki67 index); however, we observed a significant increase in the risk of
242 recurrence in the untreated patients, whereas the risk of death was similar between untreated
243 and treated patients. That adjuvant mitotane may increase significantly RFS but not OS has
244 been already reported (9),(18) and an explanation for this apparent discrepancy may be an
245 insufficient number of events to reach statistical levels of significance. In our study, however,
246 adjuvant mitotane was associated with a significant increase in OS in patients with elevated
247 Ki67 index or stage III ACC, characteristics associated with a high risk of recurrence. A recent

248 meta-analysis of the available studies demonstrated that adjuvant mitotane was linked with
249 significantly better OS despite some heterogeneity between studies attributable to the variable
250 inclusion criteria but was not able to identify predictors of response (7).

251 To the best of our knowledge, this is the first evidence supporting the concept that high-risk
252 patients should be treated with adjuvant mitotane, as recommended in previous guidelines on
253 the basis of expert opinion (6),(7). In the present study, we were able to identify factors that
254 portend a worse prognosis. Hormone secretion, elevated Weiss score and Ki67 index confer a
255 higher risk of recurrence and death, while stage III predicts shorter OS. ACC stage is generally
256 regarded as the most important prognostic factor (4),(7),(12),(21),(22) and was a strong
257 predictor of death also in our cohort. Evidence that the capability of ACC to secrete hormone
258 is a negative prognostic factor is growing (18),(23),(24) and we confirmed and extended this
259 finding showing that secreting tumours may be more aggressive due to a higher proliferation
260 rate, since they had an elevated Ki67 index compared to non-secreting ACC. This finding is
261 novel and fits well with the observation that hormone secretion is linked to a transcriptome
262 signature typical of aggressive ACC (25). We found that secreting ACCs were more frequent
263 in younger patients and in women, while hormone secretion did not affect efficacy of mitotane
264 treatment, a controversial issue in previous studies (9),(19). The Weiss score has not been
265 uniformly considered as a predictor of long-term outcome (26) while higher Ki67 index have
266 been consistently associated with poor outcome (20),(27) and a cut off at 10% has been
267 proposed to categorize patients for adjuvant treatment (7). This concept is currently tested in
268 the ongoing ADIUVO study, the first randomized controlled trial on post-operative adjuvant
269 mitotane in ACC patients (www.epiclin.it/adiuvo).

270 In our experience, toxicity associated to adjuvant mitotane was acceptable, even if we should
271 acknowledge the fact that unwanted effects might be underestimated in a retrospective analysis.
272 Severe toxicity was recorded in only 16 patients, and 11 of them were not able to tolerate

273 chronic mitotane treatment. Management of patients on adjuvant mitotane is complex, since it
274 implies specific experience to adjust supportive therapy, a careful follow-up to cope with patient
275 needs and regular monitoring of drug levels (14). Mitotane monitoring was likely a key in
276 limiting severe neurological toxicity. Our findings support the view that such patients should
277 be managed by expert centres and that a low-dose starting regimen may increase tolerability
278 and compliance. Mitotane is generally viewed as a toxic drug (28) but very few data on how
279 treatment was delivered and on related toxicity are available (8). Despite using a low-dose
280 approach, 62.8% of patients had their mitotane concentrations in the 14-20 mg/L range for at
281 least 50% of measurements. In the only study reporting about mitotane levels in an adjuvant
282 setting, <50% of patients were at target (10). We were not able to confirm a relationship
283 between the target mitotane concentration and survival advantage (29) and this may suggest
284 that lower levels could be efficacious in an adjuvant setting or that a more precise estimate of
285 chronic mitotane exposure is needed.

286 Strengths of the present study are the accurate characterization and uniform management of the
287 patients, who were cared by the same team of physicians during their disease course. This
288 allowed to capture details of mitotane treatment that were not available in previous studies. We
289 should acknowledge the limits of a retrospective analysis, although we limited bias with
290 landmark analysis and central review of pathological and radiological materials, and the fact
291 that primary surgery was done outside our institution in most patients. However, this pattern of
292 patient referral is typical of tertiary centres (17),(18),(30).

293 To conclude, our study shows that adjuvant mitotane treatment prolongs survival in non-
294 metastatic ACC patients and is effective in patients at high risk of recurrence. Use of a low-
295 dose mitotane regimen with careful patient follow up accomplishes sustained adherence to
296 therapy.

297 **Declaration of interest**

298 MT has received research grant from HRA Pharma and Novartis, and advisory board honoraria
299 from HRA Pharma. AB has received advisory board honoraria from HRA Pharma. SP has
300 received research grant from HRA Pharma. The other authors have explicitly stated that there
301 are no conflicts of interest in connection with this article.

302 Partial data of this work were presented at the ENDO 2018 and the 20th European Congress of
303 Endocrinology as posters.

304 **Funding**

305 This work was supported by a research grant from Associazione Italiana per la Ricerca sul
306 Cancro (grant number IG17678).

307 **Author contribution statement**

308 MT, and AB designed the study, interpreted the results and revised the final version. VB, SP,
309 AP, GR, and MT managed the patients. LS did hormone measurements. AC, VB, and PP
310 collected data and contributed to data interpretation. PP took care of ethic commitments. AC
311 and PB did the statistical analyses. FP did the surgical operations. AV did the central radiologic
312 review. MV did the central pathological review. AC, VB and SP wrote the first draft of the
313 report. All authors made critical revisions of the report.

314 **Acknowledgement**

315 **References**

- 316 1. Kerkhofs TMA, Verhoeven RHA, Van der Zwan JM, Dieleman J, Kerstens MN, Links
317 TP, et al. Adrenocortical carcinoma: A population-based study on incidence and survival
318 in the Netherlands since 1993. *Eur J Cancer*. 2013;49(11):2579–86.
- 319 2. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management
320 of adrenal incidentalomas: European Society of Endocrinology Clinical Practice
321 Guideline in collaboration with the European Network for the Study of Adrenal Tumors.
322 *Eur J Endocrinol*. 2016;175(2):G1--G34.
- 323 3. Gaujoux S, Mihai R, joint working group of ESES and ENSAT. European Society of
324 Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours
325 (ENSAT) recommendations for the surgical management of adrenocortical carcinoma.
326 *Br J Surg*. 2017 Mar;104(4):358–76.
- 327 4. Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P, Carbone G, et al. The
328 Italian registry for adrenal cortical carcinoma: Analysis of a multiinstitutional series of
329 129 patients. *Surgery*. 1996 Feb;119(2):161–70.
- 330 5. Terzolo M, Berruti A. Adjunctive treatment of adrenocortical carcinoma. *Curr Opin*
331 *Endocrinol Diabetes Obes*. 2008 Jun;15(3):221–6.
- 332 6. Berruti A, Baudin E, Gelderblom H, Haak H, Porpiglia F, Fassnacht M, et al. Adrenal
333 cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann*
334 *Oncol*. 2012;23:131–8.
- 335 7. Fassnacht M, Dekkers O, Else T, Baudin E, Berruti A, de Krijger RR, et al. European
336 Society of Endocrinology Clinical Practice Guidelines on the Management of
337 Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the

- 338 Study of Adrenal Tumors. *Eur J Endocrinol*. 2018;179(4):G1–46.
- 339 8. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, et al.
340 Adjuvant Mitotane Treatment for Adrenocortical Carcinoma. *N Engl J Med*.
341 2007;356(23):2372–80.
- 342 9. Berruti A, Grisanti S, Pulzer A, Claps M, Daffara F, Loli P, et al. Long-term outcomes
343 of adjuvant mitotane therapy in patients with radically resected adrenocortical
344 carcinoma. *J Clin Endocrinol Metab*. 2017;102(4):1358–65.
- 345 10. Postlewait LM, Ethun CG, Tran TB, Prescott JD, Pawlik TM, Wang TS, et al. Outcomes
346 of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution
347 Study by the US Adrenocortical Carcinoma Group. In: *Journal of the American College*
348 *of Surgeons*. NIH Public Access; 2016. p. 480–90.
- 349 11. Weiss L, Medeiros L, Vickery AJ. Pathologic features of prognostic significance in
350 adrenocortical carcinoma. *Am J Surg Pathol*. 1989;13(3):202–6.
- 351 12. Fassnacht M, Johansen S, Quinkler M, Bucszy P, Willenberg HS, Beuschlein F, et al.
352 Limited prognostic value of the 2004 International Union Against Cancer staging
353 classification for adrenocortical carcinoma. *Cancer*. 2009;115(2):243–50.
- 354 13. De Francia S, Pirro E, Zappia F, De Martino F, Sprio AE, Daffara F, et al. A new simple
355 HPLC method for measuring mitotane and its two principal metabolites. *J Chromatogr*
356 *B*. 2006 Jun 6;837(1–2):69–75.
- 357 14. Terzolo M, Ardito A, Zaggia B, Laino F, Germano A, De Francia S, et al. Management
358 of adjuvant mitotane therapy following resection of adrenal cancer. *Endocrine*.
359 2012;42(3):521–5.
- 360 15. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination

- 361 Chemotherapy in Advanced Adrenocortical Carcinoma. *N Engl J Med.* 2012
362 Jun;366(23):2189–97.
- 363 16. Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, et al. Linsitinib (OSI-
364 906) versus placebo for patients with locally advanced or metastatic adrenocortical
365 carcinoma: a double-blind, randomised, phase 3 study. *Lancet Oncol.* 2015
366 Apr;16(4):426–35.
- 367 17. Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT, et al. Recurrence
368 of Adrenal Cortical Carcinoma Following Resection: Surgery Alone Can Achieve
369 Results Equal to Surgery Plus Mitotane. *Ann Surg Oncol.* 2010;17(1):263–70.
- 370 18. Else T, Williams AR, Sabolch A, Jolly S, Miller BS, Hammer GD. Adjuvant therapies
371 and patient and tumor characteristics associated with survival of adult patients with
372 adrenocortical carcinoma. *J Clin Endocrinol Metab.* 2013;99(2):455–61.
- 373 19. Bertherat J, Coste J, Bertagna X. Adjuvant mitotane in adrenocortical carcinoma [letter
374 to the editor]. *N Engl J Med.* 2007;356:2372–80.
- 375 20. Beuschlein F, Weigel J, Saeger W, Kroiss M, Wild V, Daffara F, et al. Major prognostic
376 role of Ki67 in localized adrenocortical carcinoma after complete resection. *J Clin*
377 *Endocrinol Metab.* 2015 Mar;100(3):841–9.
- 378 21. Kebebew E, Reiff E, Duh Q-Y, Clark OH, McMillan A. Extent of disease at presentation
379 and outcome for adrenocortical carcinoma: have we made progress? *World J Surg.* 2006
380 May 10;30(5):872–8.
- 381 22. Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, et al. The European
382 Network for the Study of Adrenal Tumors staging system is prognostically superior to
383 the international union against cancer-staging system: A North American validation. *Eur*

- 384 J Cancer. 2010 Mar;46(4):713–9.
- 385 23. Berruti A, Fassnacht M, Haak H, Else T, Baudin E, Sperone P, et al. Prognostic Role of
386 Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer.
387 Eur Urol. 2014 Apr;65(4):832–8.
- 388 24. Margonis GA, Kim Y, Tran TB, Postlewait LM, Maithel SK, Wang TS, et al. Outcomes
389 after resection of cortisol-secreting adrenocortical carcinoma. Am J Surg. 2016
390 Jun;211(6):1106–13.
- 391 25. Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, et al.
392 Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer
393 Cell. 2016 Aug 8;30(2):363.
- 394 26. Volante M, Bollito E, Sperone P, Tavaglione V, Daffara F, Porpiglia F, et al.
395 Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal
396 of simplified diagnostic algorithm to prognostic stratification. Histopathology. 2009
397 Nov;55(5):535–43.
- 398 27. Morimoto R, Satoh F, Murakami O, Suzuki T, Abe T, Tanemoto M, et al.
399 Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical
400 carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical
401 carcinomas. Endocr J. 2008;55(1):49–55.
- 402 28. Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of
403 mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol. 2009
404 Sep 20;27(27):4619–29.
- 405 29. Terzolo M, Baudin AE, Ardito A, Kroiss M, Leboulleux S, Daffara F, et al. Mitotane
406 levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly

- 407 following radical resection. *Eur J Endocrinol.* 2013;169(3):263–70.
- 408 30. Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, et al.
409 Improved survival in patients with stage II adrenocortical carcinoma followed up
410 prospectively by specialized centers. *J Clin Endocrinol Metab.* 2010;95(11):4925–32.

411 **Figure 1. Study cohort.**

412

413 **Figure 2. Recurrence rate by time of follow up.**

414

415 **Figure 3. Kaplan Meier estimates of recurrence-free survival.**

416

417 **Figure 4. Recurrence-free survival curves adjusted for prognostic factors.**

418

419 **Figure 5. Kaplan Meier estimates of overall survival.**

420

421 **Figure 6. Overall survival curves adjusted for prognostic factors.**

Figure 1. Study cohort.




Figure 2. Recurrence rate by time of follow up.




Figure 3. Kaplan Meier estimates of recurrence-free survival.




Figure 4. Recurrence-free survival curves adjusted for prognostic factors.




Figure 5. Kaplan Meier estimates of overall survival.




Figure 6. Overall survival curves adjusted for prognostic factors.




Table 1. Baseline features of patients.

Characteristics	
Sex – N. (%)	
Male	58 (38.2)
Female	94 (61.8)
Age at diagnosis – yr	
Median [range]	46 [16-77]
Tumour stage – N. (%)	
Stage I-II	115 (75.7)
Stage III	37 (24.3)
Hormone secretion – N. (%)	
None	69 (45.4)
Cortisol	29 (19.1)
Cortisol + other steroids	22 (14.5)
Androgens	10 (6.6)
Aldosterone	4 (2.6)
Other hormones	7 (4.6)
No hormone work up	11 (7.2)
Type of surgery – N. (%)	
Open adrenalectomy	101 (71.6)
Laparoscopic adrenalectomy	40 (28.4)
R status – N. (%)	
R0	111 (75.0)
RX	34 (23.0)
R1	3 (2.0)
Tumor size – cm	
Median [range]	11 [3-25]
Weiss score	
Median [range]	6 [3-9]
Ki67 index – %	
Median [range]	20 [1-70]
Ki67 ≤10% – N. (%)	44 (32.8)
Ki67 >10% – N. (%)	90 (67.2)
Adjuvant treatment – N. (%)	
Mitotane	100 (65.8)
No treatment	52 (34.2)

Table 2. Baseline features of patients stratified by hormone secretion.

Characteristics	Non-secreting	Secreting	p-value
	ACC (n=69)	ACC (n=72)	
Sex – N. (%)			
Male	33 (47.8)	20 (27.8)	0.022
Female	36 (52.2)	52 (72.2)	
Age at diagnosis – yr			
Median [range]	47.0 [16-70]	41.5 [21-77]	0.014
Tumour stage – N. (%)			
Stage I-II	51 (73.9)	55 (76.4)	0.885
Stage III	18 (26.1)	17 (23.6)	
Type of surgery – N. (%)			
Open adrenalectomy	44 (65.7)	49 (74.2)	0.374
Laparoscopic adrenalectomy	23 (34.3)	17 (25.8)	
R status – N. (%)			
R0	52 (76.5)	52 (75.4)	0.850
RX	15 (22.0)	15 (21.7)	
R1	1 (1.5)	2 (2.9)	
Weiss score – Median [range]	6 [3-9]	6 [3-9]	0.162
Ki67 index – %			
Median [range]	14 [1-70]	20 [2-70]	0.025

Table 3. Baseline features of patients stratified by adjuvant treatment.

Characteristics	Mitotane group (n=100)	Control group (n=52)	p-value
Sex – N. (%)			
Male	37 (37.0)	21 (40.4)	0.817
Female	63 (63.0)	31 (59.6)	
Age at diagnosis – yr			
Median [range]	45.0 [16-77]	49.5 [18-70]	0.015
Tumour stage – N. (%)			
Stage I-II	77 (77.0)	38 (73.1)	0.580
Stage III	23 (23.0)	14 (26.9)	
Hormone secretion – N. (%)			
Non-secreting tumor	41 (41.0)	28 (53.8)	0.154
Secreting tumor	52 (52.0)	20 (38.5)	
No hormone work up	7 (7.0)	4 (7.7)	
Type of surgery – N. (%)			
Open adrenalectomy	67 (72.0)	34 (70.8)	0.467
Laparoscopic adrenalectomy	26 (28.0)	14 (29.2)	
R status – N. (%)			
R0	71 (74.0)	40 (76.9)	0.435
RX	22 (22.9)	12 (23.1)	
R1	3 (3.1)		
Weiss score – Median [range]	6 [3-9]	5 [3-9]	0.014
Ki67 index – %			
Median [range]	20 [1-70]	11 [1-70]	0.001

Table 4. Adverse events of mitotane therapy.

Type of toxicity – <i>N.</i> (%)	
Gastrointestinal	6 (37.5)
Hepatic	3 (18.8)
Haematological	1 (6.3)
Neurological	3 (18.7)
Other	3 (18.7)

Table 5. Univariate analyses of predictive factors of RFS and OS.

Factor	RFS			OS		
	HR	95% CI	<i>p</i> -value	HR	95% CI	<i>p</i> -value
Sex ¹	0.93	0.62-1.40	0.74	0.81	0.49-1.35	0.42
Age at diagnosis	0.98	0.70-1.39	0.93	0.97	0.63-1.50	0.90
Tumour stage ²	2.21	1.43-3.43	<0.001	2.41	1.46-3.99	<0.001
Hormone secretion ³	1.82	1.14-2.86	0.01	1.67	0.94-2.94	0.08
Cortisol secretion ⁴	1.15	0.62-2.13	0.66	1.01	0.51-2.04	0.97
Type of surgery ⁵	0.73	0.45-1.17	0.19	0.72	0.39-1.33	0.29
R status ⁶	1.06	0.67-1.68	0.82	0.72	0.39-1.31	0.28
Weiss score	1.75	1.33-2.29	<0.001	1.75	1.28-2.39	<0.001
Ki67 index	1.57	1.21-2.03	<0.001	1.80	1.33-2.43	<0.001
Mitotane treatment	1			1		
No treatment	1.81	1.20-2.73	0.005	1.05	0.63-1.76	0.85

Reference for categorical variables: ¹Male sex, ²ACC stage III, ³Secreting tumours, ⁴Cortisol secretion, ⁵Laparoscopic surgery, ⁶RX-R1.

Reference for continuous variables: HR was calculated comparing interquartile ranges.

Table 6. Multivariate analyses of predictive factors of RFS and OS.

Factor	RFS			OS		
	HR	95% CI	<i>p</i> -value	HR	95% CI	<i>p</i> -value
Sex ¹	0.93	0.57-1.52	0.77	0.80	0.44-1.46	0.47
Age at diagnosis	1.20	0.80-1.81	0.37	1	0.60-1.65	0.98
Tumour stage ²	1.41	0.78-2.54	0.25	2.26	1.20-4.25	0.01
Hormone secretion ³	2.78	1.61-4.76	<0.001	2.08	1.11-4.00	0.02
Weiss score	1.69	1.24-2.32	0.001	1.47	1.02-2.12	0.04
Ki67 index	1.71	1.23-2.38	0.001	1.73	1.16-2.60	0.008
Mitotane treatment	1			1		
No treatment	2.79	1.58-4.91	<0.001	1.22	0.61-2.42	0.57

Reference for categorical variables: ¹Male sex, ²Stage III, ³Secreting tumours.

Reference for continuous variables: HR was calculated comparing interquartile ranges.

Table 7. Risk of recurrence and death in patients treated with adjuvant mitotane.

ACC characteristics	RFS			OS		
	HR	95%CI	<i>p</i> -value	HR	95%CI	<i>p</i> -value
Stage III	0.96	0.32-2.92	0.95	0.21	0.06-0.78	0.02
Hormone secretion	0.58	0.21-1.62	0.30	2.53	0.69-9.37	0.16
Ki67 index ¹	0.97	0.94-0.99	0.02	0.94	0.90-0.98	0.005

¹ HR of Ki67 index per 1% increase.